Emgality 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued2 / 
affected3  
amended 
on 
R/0023 
Renewal of the marketing authorisation. 
20/07/2023 
01/09/2023 
IB/0026 
B.I.e.5.c - Implementation of changes foreseen in an 
14/07/2023 
n/a 
approved change management protocol - For a 
biological/immunological medicinal product 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
IB/0025 
B.I.e.5.c - Implementation of changes foreseen in an 
29/06/2023 
n/a 
approved change management protocol - For a 
biological/immunological medicinal product 
PSUSA/10733
Periodic Safety Update EU Single assessment - 
14/04/2023 
n/a 
PRAC Recommendation - maintenance 
/202209 
galcanezumab 
IA/0024 
B.II.e.7.b - Change in supplier of packaging 
13/02/2023 
n/a 
components or devices (when mentioned in the 
dossier) - Replacement or addition of a supplier 
IG/1565 
A.5.b - Administrative change - Change in the name 
06/12/2022 
n/a 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
IAIN/0020/G 
This was an application for a group of variations. 
11/11/2022 
01/09/2023 
Annex II and 
PL 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
A.7 - Administrative change - Deletion of 
manufacturing sites 
PSUSA/10733
Periodic Safety Update EU Single assessment - 
19/05/2022 
15/07/2022 
SmPC and PL 
Refer to Scientific conclusions and grounds recommending 
/202109 
galcanezumab 
the variation to terms of the Marketing Authorisation(s)’ for 
Page 2/5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IA/0019 
B.II.e.7.b - Change in supplier of packaging 
14/06/2022 
n/a 
components or devices (when mentioned in the 
dossier) - Replacement or addition of a supplier 
PSUSA/10733/202109. 
PSUSA/10733
Periodic Safety Update EU Single assessment - 
28/10/2021 
n/a 
PRAC Recommendation - maintenance 
/202103 
galcanezumab 
PSUSA/10733
Periodic Safety Update EU Single assessment - 
20/05/2021 
16/07/2021 
SmPC and PL 
Refer to Scientific conclusions and grounds recommending 
/202009 
galcanezumab 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/10733/202009. 
PSUSA/10733
Periodic Safety Update EU Single assessment - 
29/10/2020 
n/a 
PRAC Recommendation - maintenance 
/202003 
galcanezumab 
IAIN/0015 
B.II.b.2.c.1 - Change to importer, batch release 
14/07/2020 
n/a 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
II/0013 
B.II.b.4.c - Change in the batch size (including batch 
18/06/2020 
n/a 
size ranges) of the finished product - The change 
requires assessment of the comparability of a 
biological/immunological medicinal product or a new 
bioequivalence study 
PSUSA/10733
Periodic Safety Update EU Single assessment - 
17/04/2020 
n/a 
PRAC Recommendation - maintenance 
/201909 
galcanezumab 
II/0009 
Update of sections 4.2 and 5.1 of the SmPC following 
26/03/2020 
07/01/2021 
SmPC and PL 
The SmPC section 4.2 and 5.1 has been updated to reflect 
Page 3/5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
final results from a CONQUER study (A Randomized, 
Double-Blind, Placebo-Controlled Study of 
Galcanezumab in Adults with Treatment-Resistant 
Migraine; the Package Leaflet is updated accordingly. 
In addition, the Marketing authorisation holder 
(MAH) took the opportunity correct to Slovakian 
contact information in the Package Leaflet. 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
the results of the study conducted in patients with 
treatment resistant migraine.  
The PL have been updated accordingly. 
N/0012 
Minor change in labelling or package leaflet not 
16/03/2020 
07/01/2021 
PL 
connected with the SPC (Art. 61.3 Notification) 
IA/0011 
A.6 - Administrative change - Change in ATC 
20/01/2020 
07/01/2021 
SmPC 
Code/ATC Vet Code 
PSUSA/10733
Periodic Safety Update EU Single assessment - 
17/10/2019 
09/12/2019 
SmPC and PL 
Refer to Scientific conclusions and grounds recommending 
/201903 
galcanezumab 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/10733/201903. 
IB/0008 
B.I.a.2.a - Changes in the manufacturing process of 
07/08/2019 
n/a 
the AS - Minor change in the manufacturing process 
of the AS 
IB/0007/G 
This was an application for a group of variations. 
31/07/2019 
n/a 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
Page 4/5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
IA/0006 
B.I.b.1.c - Change in the specification parameters 
16/07/2019 
n/a 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition of a new 
specification parameter to the specification with its 
corresponding test method 
IAIN/0003 
B.II.b.1.a - Replacement or addition of a 
08/02/2019 
n/a 
manufacturing site for the FP - Secondary packaging 
site 
IAIN/0002 
B.II.e.5.a.1 - Change in pack size of the finished 
18/12/2018 
09/12/2019 
SmPC, 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
Labelling and 
PL 
IAIN/0001 
B.II.e.5.a.1 - Change in pack size of the finished 
18/12/2018 
09/12/2019 
SmPC, 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
Labelling and 
PL 
Page 5/5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
